Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
AsclepiX Completes Enrollment in DISCOVER Trial for Wet AMD
AsclepiX Therapeutics has successfully completed the enrollment for the DISCOVER trial (NCT05859776), which evaluates the safety and tolerability of three different doses of AXT107 (gersizangitide) in patients with wet Age-related Macular Degeneration (AMD). Trial Design and Objectives The trial includes…
Novel Gene Therapy Improves Vision in Children with LCA
In a landmark clinical trial, CRISPR-Cas9 gene editing has proven safe and effective in treating a form of inherited blindness, marking a significant milestone in genetic medicine. The multi-site BRILLIANCE trial, involving the Perelman School of Medicine at the University…
EyePoint’s Duravyu Misses Phase 2 NPDR Trial Goal
EyePoint Pharmaceuticals announced the topline results from its phase 2 PAVIA clinical trial, which evaluated the efficacy of Duravyu (vorolanib intravitreal insert), formerly known as EYP-1901, in treating non-proliferative diabetic retinopathy (NPDR). The trial revealed that Duravyu did not achieve…
Lumibird Launches C.DIAG for Dry Eye Disease
Lumibird Medical has unveiled its latest innovation, the C.DIAG, marking a significant advancement in dry eye diagnostic technology. Integrated with AI algorithms, this new component of the C.SUITE is designed to enable the diagnosis, treatment, and education of dry eye…
FDA Accepts Eluminex’s IND for DME Antibody
Eluminex Biosciences announced the acceptance of its EB-105 Investigational New Drug (IND) application by the FDA. This significant milestone marks a pivotal moment in the advancement of medical science, particularly in the realm of Diabetic Macular Edema (DME) treatment. EB-105:…
Emmecell Completes Dosing in Key Corneal Edema Trial
Emmetrope Ophthalmics, a leader in cell-based therapies for severe eye diseases, today announced the completion of the final dose administration in its U.S. clinical trial for EO2002, targeting the treatment of corneal edema. EO2002 Advances Toward Phase 3 This milestone…
RetiSpec, Topcon Collaborate on Eye-Based AI Diagnostic Tool
Topcon Healthcare has announced an investment in RetiSpec, marking the beginning of a collaboration aimed at commercializing RetiSpec’s innovative technology. This partnership intends to bridge the gap between neurology and eye care, potentially transforming how Alzheimer’s disease is detected and…
FDA Clears AEYE Health’s Autonomous AI for DR Screening
AEYE Health has received FDA clearance for its fully autonomous AI, making it the first to diagnose referable diabetic retinopathy using a handheld camera. The technology, known as AEYE Diagnostic Screening (AEYE-DS), was previously approved for use with a tabletop…
Inflammasome Therapeutics Begins GA Clinical Trial
Inflammasome Therapeutics has officially dosed the first patient in a pioneering clinical trial aimed at treating geographic atrophy (GA) resulting from age-related macular degeneration (AMD). This trial, a first-in-class study for a sustained release implant, is sponsored by the University…
OpenAI’s Sora in ophthalmology: revolutionary generative AI in eye health – Nature
OpenAI’s Sora in ophthalmology: revolutionary generative AI in eye health Nature Source: Author: | Date: 2024-04-30 07:00:00 Source: Author: | Date: 2024-04-30 07:00:00